Astragalus Salvia compound may directly regulate biological processes and genes in endothelial cell activation and injury and placental or trophoblast cell ischemia models to treat pregnancy-induced hypertension.
Network pharmacology analysis suggests that Astragalus Salvia compound may treat pregnancy-induced hypertension by regulating pathways related to endothelial cell activation and placental ischemia.
To uncover the pharmacological mechanism of Astragalus Salvia compound (ASC) on pregnancy-induced hypertension syndrome (PIH), to provide useful information for clinical, as well as to connect the basic and clinical by a network pharmacological approach, we used network pharmacological approach. We collected ASC's compounds by traditional Chinese Medicine databases, and input them into PharmMapper to got their targets. Then we acquired PIH targets from Genecards and OMIM, collected the interactions of all the targets and other human proteins via String and INACT. We also constructed the network by Cytoscape and analyze it by MCODE so as to get clusters. Finally, we put all the targets of clusters into DAVID to do GO enrichment analysis. After these, four networks are constructed by Cytoscape; they are PIH network, compound-compound target network of ASC, ASC-PIH network, and compound target-PIH target-other human proteins' PPI network. According to the results, we think that ASC may directly regulate several biological processes and their genes in "endothelial cell activation and injury" and "placental or trophoblast cell ischemia" models to treat PIH. And it may indirectly act on the rest of the biological process to treat PIH or may not.
Zeng et al. (2017) studied Pregnancy-Induced Hypertension Syndrome (PIH). Astragalus Salvia compound (ASC) was evaluated. Astragalus Salvia compound may directly regulate biological processes and genes in endothelial cell activation and injury and placental or trophoblast cell ischemia models to treat pregnancy-induced hypertension.